Welcome to AVM Biotechnology’s ASH 2022 Virtual Booth
We are excited to meet with you in the ASH virtual space and to introduce you to AVM Biotechnology and AVM0703. An invitation from our Founder and CSO:
AVM0703 triggers the production and release of endogenous bispecific gamma delta+ Natural Killer T-cells (AVM-NKT). These naturally occurring supercharged immune cells have unique properties and appear rapidly in the blood following a single dose of AVM0703. Preclinical data indicate that AVM0703 potentiates chemotherapy. It also has activity in solid tumors and autoimmune disorders.